EMA’s PRIME to Speed Sage’s Plans For Postpartum Depression
Executive Summary
Sage Therapeutics’ investigational drug for postpartum depression is the 14th product to pass the tough entry criteria for the European Medicines Agency’s popular priority medicines (PRIME) scheme for drugs targeting an unmet medical need.